Artikel
Do routine blood values correlate with the recurrence or the 10 year survival rate of head and neck cancer?
Suche in Medline nach
Autoren
Veröffentlicht: | 22. September 2005 |
---|
Gliederung
Text
The following data was derived from a prospective, randomised, multi-centre trial of patients with head and neck cancer. This trial evaluated an adjuvant mistletoe treatment and demonstrated no beneficial effects in head and neck cancer patients (Eur J Cancer 2001; 37:23-31). The current question is: do values of routine blood examinations or acute phase proteins correlate with the recurrence or the 10 year survival rate of head and neck carcinoma?
Method: Here, 362 patients were randomly selected and blood samples were taken at up to 12 different time points (before treatment and after 8,12,16,22,28,32,44,48,60,72, or 84 weeks of treatment). The examined parameters were: γ-GT, GOT, GPT, haemoglobin, haptoglobin, CRP, α1-glykoprotein, fibrinogen und differentiated blood count.
Before treatment these patients had the following stage grouping and primary localization: I : (n=76), II (n=77), III (n=74), IV (n=135). Oral cavity (n=58), oropharynx (n=99), hypopharynx (n=60), larynx (n=136) [lips (n=6)]. The median follow up time was 80 months.
Results: The average and standard deviation were calculated for the different time points. Before treatment there was a correlation between the stage grouping and GPT, haemoglobin, CRP, α1-glykoprotein und fibrinogen. There was no difference in any parameter for the different tumour localizations. When compared to the baseline, none of the parameters correlated with the relative risk of disease free survival or the over all survival. Furthermore, there was no correlation of any parameter over the follow up period.
Thus, none of the above routine blood sample values can serve as a predicting factor in head and neck cancer patients.
Kindly supported by BMBS; Wilhelm Sander-Foundation; Matthias Lackas-Foundation